Kardigan clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 / 3 2 trials

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen. After: Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels.

Planned enrollment increased by 40 participants

Before: 100 participants (planned). After: 140 participants (planned).

Primary completion date changed

Before: 29 Dec 2026. After: Dec 2026.

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48. After: Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48.

Planned enrollment decreased by 134 participants

Before: 1410 participants (planned). After: 1276 participants (planned).

Phase changed

Before: PHASE3. After: PHASE2, PHASE3.

Check registry source